Drug Approval | November 22, 2023
Lupin receives approval from USFDA for Pitavastatin Tablets
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)